Stock data
Taysha Gene Therapies, Inc. (TSHA)
Taysha Gene Therapies, Inc. (TSHA) reported revenue of US$9.77M and net income of -US$109.00M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$9.77M | — | -US$110.50M | -US$109.00M | — |
| 2024 | US$8.33M | — | -US$91.46M | -US$89.30M | — |
| 2023 | US$15.45M | — | -US$72.44M | -US$111.57M | — |
| 2022 | US$2.50M | — | -US$162.45M | -US$166.01M | — |
| 2021 | — | — | -US$173.27M | -US$174.52M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$0.00M | -US$46.64M | — |
| 2026-03-31 | US$0.00M | -US$42.41M | — |
| 2025-12-31 | US$5.49M | -US$27.85M | — |
| 2025-09-30 | US$0.00M | -US$32.73M | — |
| 2025-06-30 | US$1.99M | -US$26.88M | — |
| 2025-03-31 | US$2.30M | -US$21.53M | — |
| 2024-12-31 | US$2.02M | -US$18.79M | — |
| 2024-09-30 | US$1.79M | -US$25.52M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.